AZD-3463

AZD-3463 (ALK/IGF1R inhibitor) is an orally active ALK/IGF1R inhibitor, with a Ki of 0.75 nM for ALK. AZD3463 induces apoptosis and autophagy in neuroblastoma cells[1][2][3].

Product Specifications

CAS Number

[1356962-20-3]

Product Name Alternative

ALK/IGF1R inhibitor

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Anaplastic lymphoma kinase (ALK) ; Apoptosis; Autophagy; IGF-1R

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Endocrinology

Assay Protocol

https://www.medchemexpress.com/azd-3463.html

Concentration

10mM

Purity

99.31

Solubility

DMSO : 20 mg/mL (ultrasonic)

Smiles

ClC(C=NC(NC1=C(OC)C=C(N2CCC(N)CC2)C=C1)=N3)=C3C4=CNC5=C4C=CC=C5

Molecular Formula

C24H25ClN6O

Molecular Weight

448.95

Precautions

H302, H315, H319, H335

References & Citations

[1]Yongfeng Wang, et al. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis. Sci Rep. 2016; 6: 19423.|[2]Sausan A. Moharram, et al. The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia. Blood Cancer J. 2019 Feb; 9 (2) : 5.|[3]Ozates NP, et al. Effects of rapamycin and AZD3463 combination on apoptosis, autophagy, and cell cycle for resistance control in breast cancer. Life Sci. 2021 Jan 1;264:118643.